Pharmafile Logo

Dedicated

- PMLiVE

Merck presents positive results for Keytruda plus chemotherapy in breast cancer

Triple-negative breast cancer accounts for 24% of all newly diagnosed cancers worldwide

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

- PMLiVE

Navigating Food Allergy Management: Trends, Treatments, and Decision-Making

Are you having trouble navigating the management of food allergies? Join our faculty experts for a live conversation on social media to learn about the evolving complexities in food allergy...

Medscape Education

- PMLiVE

How to unlock the value of congress: strategies to expand reach, learning and clinical application

Medical congresses are pivotal landmarks in the healthcare calendar. But is their value as a source of the latest and most cutting-edge scientific information being leveraged to its full potential,...

EPG Health

- PMLiVE

A clear and present danger

Consulting is a dangerous business – maybe never more so than now

- PMLiVE

The Power of Patient Insights to Improve Cancer Care

Two global patient advocacy groups—The Lymphoma Coalition and Lung Cancer Europe— are compiling data from their communities on the real-world experience of living with cancer. What the data reveals sometimes...

Medscape Education

- PMLiVE

Medscape Education Continues Its Patient-Centric Mission at EHA 2024

Anticipation is building at Medscape Education as the team prepares for the EHA 2024 Congress. Medscape Education is excited to announce a significant presence during the congress including a Medscape...

Medscape Education

- PMLiVE

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn

The company will expand its immunology portfolio by gaining global rights to YJT’s NM26 in atopic dermatitis

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links